Publikationen in Zusammenarbeit mit Forschern von Universidad del País Vasco/Euskal Herriko Unibertsitatea (26)

2024

  1. An in vitro analysis of the interaction between infliximab and granulocyte–monocyte apheresis

    Gastroenterologia y Hepatologia, Vol. 47, Núm. 4, pp. 347-351

  2. Clinical and treatment outcomes of a second subcutaneous or intravenous anti-TNF in patients with ulcerative colitis treated with two consecutive anti-TNF agents: data from the ENEIDA registry

    Therapeutic Advances in Gastroenterology, Vol. 17

  3. Evaluation of Genetic Variants Associated with the Risk of Thiopurine-Related Pancreatitis: A Case Control Study from ENEIDA Registry

    Digestive Diseases, Vol. 42, Núm. 3, pp. 257-264

  4. m6A Methylated Long Noncoding RNA LOC339803 Regulates Intestinal Inflammatory Response

    Advanced Science, Vol. 11, Núm. 13

2023

  1. Effectiveness and Safety of Ustekinumab in Elderly Patients with Crohn's Disease: Real World Evidence From the ENEIDA Registry

    Journal of Crohn's & colitis, Vol. 17, Núm. 1, pp. 83-91

  2. Mitochondrial dysfunction-associated microbiota establishes a transmissible refractory response to anti-TNF therapy during ulcerative colitis

    Gut Microbes, Vol. 15, Núm. 2

2022

  1. Gluten-induced RNA methylation changes regulate intestinal inflammation via allele-specific XPO1 translation in epithelial cells

    Gut, Vol. 71, Núm. 1, pp. 68-77

  2. Immigrant IBD Patients in Spain Are Younger, Have More Extraintestinal Manifestations and Use More Biologics Than Native Patients

    Frontiers in Medicine, Vol. 9

  3. Management and Long-term Outcomes of Crohn's Disease Complicated with Enterocutaneous Fistula: ECUFIT Study from GETECCU

    Journal of Crohn's & colitis, Vol. 16, Núm. 7, pp. 1049-1058

  4. Nationwide COVID-19-EII Study: Incidence, Environmental Risk Factors and Long-Term Follow-Up of Patients with Inflammatory Bowel Disease and COVID-19 of the ENEIDA Registry

    Journal of Clinical Medicine, Vol. 11, Núm. 2

2021

  1. A Novel Noninvasive Method Based on Salivary Inflammatory Biomarkers for the Screening of Celiac Disease

    Cellular and Molecular Gastroenterology and Hepatology

  2. European registry on helicobacter pylori management: Effectiveness of first and second-line treatment in Spain

    Antibiotics, Vol. 10, Núm. 1, pp. 1-15

2019

  1. Clinical Characteristics, Associated Malignancies and Management of Primary Sclerosing Cholangitis in Inflammatory Bowel Disease Patients: A Multicentre Retrospective Cohort Study

    Journal of Crohn's & colitis, Vol. 13, Núm. 12, pp. 1492-1500

  2. Prevalence and Factors Associated with Fatigue in Patients with Inflammatory Bowel Disease: A Multicentre Study

    Journal of Crohn's and Colitis, Vol. 13, Núm. 8, pp. 996-1002

2017

  1. Effectiveness of adalimumab for the treatment of ulcerative colitis in clinical practice: comparison between anti-tumour necrosis factor-naïve and non-naïve patients

    Journal of Gastroenterology, Vol. 52, Núm. 7, pp. 788-799

  2. Erratum to: Effectiveness of adalimumab for the treatment of ulcerative colitis in clinical practice: comparison between anti-tumour necrosis factor-naïve and non-naïve patients (J Gastroenterol, 10.1007/s00535-016-1274-1)

    Journal of Gastroenterology

2015

  1. A randomized controlled trial of a 10week group psychotherapeutic treatment added to standard medical treatment in patients with functional dyspepsia

    Journal of Psychosomatic Research, Vol. 78, Núm. 6, pp. 563-568

  2. Effectiveness of adalimumab in perianal fistulas in Crohn's disease patients naive to Anti-TNF therapy

    Journal of Clinical Gastroenterology, Vol. 49, Núm. 1, pp. 34-40

2013

  1. Prognosis and follow-up of 135 patients with ischemic colitis over a five-year period

    World Journal of Gastroenterology, Vol. 19, Núm. 44, pp. 8042-8046

2005

  1. Health-related quality of life and appropriateness of cholecystectomy

    Annals of Surgery, Vol. 241, Núm. 1, pp. 110-118